Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial

Veronica Villani, Chiara Zucchella, Giovanni Cristalli, Edvina Galiè, Francesco Bianco, Diana Giannarelli, Silvia Carpano, Giuseppe Spriano, Andrea Pace

Research output: Contribution to journalArticle


Background Few studies have investigated the effect of Vitamin E in reducing the cisplatin (CDDP)-induced ototoxicity. This study evaluated Vitamin E supplementation as a protecting agent against CDDP-induced ototoxicity. Methods Patients who started CDDP were randomly assigned to receive Vitamin E supplementation at 400 mg per day (group 1) or placebo (group 2). Audiograms and evoked brainstem responses were obtained at baseline, and after 1, 2, and 3 months. Results Twenty-three patients affected by solid malignancies were enrolled (13 in group 1 and 10 in group 2). At 1 month, a significant hearing loss in group 2 at both 2000 HZ (right ear: p =.05; left ear: p =.04) and 8000 HZ (right ear: p =.04; left ear: p =.03) was detected when compared to baseline values. Audiograms did not show significant changes. At 1 month, evoked brainstem responses remained unchanged in both arms without significant differences between groups. Conclusion These preliminary findings confirm the neuroprotective properties of Vitamin E against the CDDP-induced ototoxicity.

Original languageEnglish
Pages (from-to)E2118-E2121
JournalHead and Neck
Publication statusPublished - Apr 1 2016



  • antioxidant
  • cisplatin
  • neuroprotection
  • ototoxicity
  • Vitamin E

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this